1. Home
  2. HSDT vs BIOA Comparison

HSDT vs BIOA Comparison

Compare HSDT & BIOA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

HSDT

Helius Medical Technologies Inc. (DE)

HOLD

Current Price

$3.06

Market Cap

165.6M

Sector

Health Care

ML Signal

HOLD

Logo BioAge Labs Inc.

BIOA

BioAge Labs Inc.

HOLD

Current Price

$12.47

Market Cap

175.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HSDT
BIOA
Founded
N/A
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
165.6M
175.7M
IPO Year
N/A
2024

Fundamental Metrics

Financial Performance
Metric
HSDT
BIOA
Price
$3.06
$12.47
Analyst Decision
Buy
Analyst Count
0
4
Target Price
N/A
$11.33
AVG Volume (30 Days)
724.6K
410.3K
Earning Date
11-18-2025
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$941,000.00
$5,917,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$75.13
N/A
P/E Ratio
N/A
N/A
Revenue Growth
87.45
N/A
52 Week Low
$2.83
$2.88
52 Week High
$1,200.00
$13.10

Technical Indicators

Market Signals
Indicator
HSDT
BIOA
Relative Strength Index (RSI) 31.81 77.17
Support Level $3.83 $12.00
Resistance Level $4.32 $13.10
Average True Range (ATR) 0.40 0.72
MACD 0.14 0.26
Stochastic Oscillator 2.63 87.28

Price Performance

Historical Comparison
HSDT
BIOA

About HSDT Helius Medical Technologies Inc. (DE)

Solana Co is a publicly listed digital asset treasury established in partnership with Pantera and Summer Capital. The company is dedicated to acquiring Solana (SOL) and aims to maximize SOL per share by strategically leveraging capital market opportunities and on-chain activities. Through this model, Solana Company provides public market investors with efficient and direct exposure to Solana's long-term growth potential.

About BIOA BioAge Labs Inc.

Bioage Labs Inc is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Its focus is metabolic disease, one of the greatest healthcare challenges. The pipeline Products of the company are NLRP3 inhibitors, APJ against, and others.

Share on Social Networks: